18518715. METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS simplified abstract (Genentech, Inc.)
Contents
- 1 METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS
Organization Name
Inventor(s)
Claudio Ciferri of South San Francisco CA (US)
Evan Michael Green of South San Francisco CA (US)
Marc Kschonsak of South SAn Francisco CA (US)
METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18518715 titled 'METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS
Simplified Explanation
The patent application describes methods of treating or preventing human cytomegalovirus (HCMV) infection by modulating interactions between the HCMV gH/gL/UL128-131A pentamer and host cell proteins on the plasma membrane, as well as methods of identifying modulators of these interactions.
- Modulating interactions between the HCMV gH/gL/UL128-131A pentamer and host cell proteins on the plasma membrane
- Identifying modulators of these interactions
Potential Applications
This technology could be applied in the development of new antiviral therapies targeting human cytomegalovirus (HCMV) infection.
Problems Solved
This technology addresses the need for more effective treatments for HCMV infection, a common and potentially serious viral infection in humans.
Benefits
The benefits of this technology include potentially improved outcomes for patients with HCMV infection, reduced viral replication, and the development of novel antiviral drugs.
Potential Commercial Applications
One potential commercial application of this technology could be the development of new antiviral drugs targeting HCMV infection.
Possible Prior Art
Prior art may include existing antiviral therapies for HCMV infection, such as ganciclovir, foscarnet, and cidofovir.
Unanswered Questions
How does this technology compare to existing antiviral therapies for HCMV infection?
This article does not provide a direct comparison between this technology and existing antiviral therapies for HCMV infection.
What are the potential side effects of modulating interactions between the HCMV gH/gL/UL128-131A pentamer and host cell proteins?
This article does not address the potential side effects of modulating these interactions.
Original Abstract Submitted
Provided herein are methods of treating or preventing human cytomegalovirus (HCMV) infection comprising modulating interactions between the HCMV gH/gL/UL128-131A pentamer and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
